Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
13 Nov 2020
byRoshini Claire Anthony
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
13 Nov 2020
